 
    Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles.
Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.Cormorant Asset Management was founded in 2013 and is based in Boston, Massachusetts, United States.
| 
                        Date
                        Company Name
                     | Round | Money Raised | Industry | Lead Investor | 
|---|---|---|---|---|
| 
                      Aug 12, 2022
                      
                            Greenlight Biosciences | Post-IPO Equity | $109M | Agriculture | — | 
| 
                      Apr 19, 2022
                      
                            Tessera Therapeutics | Series C | $300M | Biopharma | — | 
| 
                      Feb 16, 2022
                      
                            Star Therapeutics | Series Unknown | $100M | — | |
| 
                      Feb 3, 2022
                      
                            Greenlight Biosciences | Post-IPO Equity | $125.50M | Agriculture | — | 
| 
                      Jul 13, 2021
                      
                            Prime Medicine | Series B | $200M | Biotechnology | — |